Ascelia Pharma AB (publ) (ticker: ACE) today announces that the Nomination Committee in preparation for the Annual General Meeting (AGM) on 5 May 2022 has been appointed
In accordance with the instructions for the Nomination Committee in Ascelia Pharma, the Nomination Committee shall consist of four members representing the three largest shareholders together with the chairman of the board of directors. The “three largest shareholders” refer to the ownership grouped registered or in any other way known shareholders as per the end of September.
Based on the above, the Nomination Committee in respect of the AGM that will be held in Malmö on 5 May 2022 has been established to consist of the following persons together representing approximately 25% of votes in the company:
- Jørgen Thorball, chairman of the Nomination Committee, appointed by Sunstone Life Science Ventures II K/S;
- Håkan Nelson, appointed by Øresund Healthcare Capital;
- Marianne Flink, appointed by The Fourth Swedish National Pension Fund (AP4); and
- Peter Benson, chairman of the board of directors.
The Nomination Committee’s proposals will be presented in the notice to the Annual General Meeting 2022 and on the company’s website, www.ascelia.com.
The duties of the Nomination Committee is to prepare and propose the following to the coming annual shareholders’ meeting: election of chairman at the shareholders’ meeting; election of chairman of the board of directors and other members of the board of directors; fees to the board of directors, divided between the chairman and other members, and any fees for committee work; election of auditor and fees to the auditor; and principles for appointment of the Nomination Committee.
Shareholders who wish to submit proposals to the Nomination Committee are welcome to contact the Nomination Committee at the company’s address or alternatively via e-mail kb@ascelia.com. Proposals shall be submitted in due time before the Annual General Meeting, but not later than 4 February 2022, to ensure that the proposals can be considered by the Nomination Committee.